Radiation therapy and biological compounds for consolidation therapy in advanced ovarian cancer

International Journal of Gynecological Cancer

Volumn 18, Issue SUPPL. 1, 2008, Pages 44-46

  Auranen, A ^a   Grenman S ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Biological compounds; Consolidation therapy; Ovarian cancer; Radiation therapy; Radionuclides

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CARBOPLATIN; GAMMA INTERFERON; MATRIX METALLOPROTEINASE INHIBITOR; OREGOVOMAB; PACLITAXEL; PHOSPHORUS 32; RADIOISOTOPE; TANOMASTAT; YTTRIUM 90;

ADVANCED CANCER; CANCER RADIOTHERAPY; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; NEOPLASM STAGING; OVARIAN NEOPLASMS; RADIOTHERAPY;

EID: 40749105779     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01105.x     Document Type: Review

References (15)

1. Dearnley DD, McMeekin DS. Consolidation therapy in ovarian cancer: where do we stand? Curr Opin Obstet Gynecol 2006 18 : 3 7.
2. Thomas GM. Is there a role for consolidation or salvage radiotherapy after chemotherapy in advanced ovarian cancer? Gynecol Oncol 1993 51 : 97 103.
3. Sorbe B. Consolidation treatment of advanced ovarian carcinoma with radiotherapy after induction chemotherapy. Int J Gynecol Cancer 2003 13 (Suppl. 2 192 5.
4. Petit T, Yelten M, d'Hombres A et al. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy. Gynecol Oncol 2007 104 : 104 8.
5. 32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J Clin Oncol 2003 21 : 2849 55.
6. Verveijen RH, Massiger LF, Benigno BB et al. Phase III trial of intraperitoneal therapy with yttrium -90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically definied complete remission. J Clin Oncol 2006 24 : 571 8.
7. Darcy KM, Schilder RJ. Relevant molecular markers and targets. Gynecol Oncol 2006 103 : S6 S13.
8. Windbichler GH, Hausmaninger H, Stumwoll W et al. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 2000 82 : 1138 44.
9. Hirte H, Vergote IB, Jeffrey JR et al. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy : a National Cancer Institute of Canada Clinical Trial Group Study. Gynecol Oncol 2006 102 : 300 8.
10. Ehlen TG, Gordon AN, Fingert HJ et al. Adjuvant treatment with monoclonal antibody, OvaRex Mab-B43.13 (OV) targeting CA125, induces robust immune responses associated with prolonged time to relapse (TTR) in a randomized, placebo-controlled study in patients (pts) with advanced epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 2002 21 : 9a (abstract 31)
11. Berek, Taylor PT, Gordin A et al. Randomized, placebo-controlled study of oregovomab for consolidation on clinical remission in patients with advanced ovarian cancer. J Clin Oncol 2004 22 : 3507 16.
12. Hall GD, Brown JM, Coleman RE et al. Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomized phase III study. Br J Cancer 2004 91 : 621 6.
13. Aghajanian C. The role of bevacizumab in ovarian cancer - an evolving story. Gynecol Oncol 2006 102 : 131 3.
14. Penson RT, Cannistra SA, Seiden MV et al. Phase II study on carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced mullerian tumors. J Clin Oncol ASCO Annual Meeting Proceedings. J Clin Oncol 2006 24 : 240s.
15. Sabbatini P, Spriggs DR. Consolidation for ovarian cancer remission. J Clin Oncol 2006 24 : 537 8.